IEX •
Healthcare •
Biotechnology •
Quote as of 07/28/2026 15:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization535.76 mln
Float13.17 mln
Earnings Date08/13/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
43.85
Transformational upside
Relative Strength
0
/ 100
Severely lagging
Debt / Equity
0.01
Debt-free
ROE
-79.89
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
MapLight Therapeutics is a clinical-stage drug development company focused on treating serious brain and nervous system conditions, including schizophrenia, Parkinson's disease, autism spectrum disorder, and Alzheimer's disease. The company builds its treatments around a research platform designed to identify the specific brain circuits involved in each condition and develop drugs that target those circuits directly. Founded in 2018 and headquartered in Redwood City, California, MapLight has several drug candidates at various stages of development.
